Crescendo Biologics Limited (Crescendo) today announces it has raised a further £2m ($3.3m), from EMBL Ventures, in a final close of its Series A financing. Originally announced in December 2013, the Series A now totals £19.5m. It was led by Imperial Innovations and included new investor Astellas Venture Management (AVM). Founding seed investor Sofinnova Partners also contributed significantly to the round.